CD19 CAR T-cell therapy for tough B-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either relapsed/refractory B-cell ALL with CD19 (for some cases) or relapsed/refractory large B-cell lymphoma after at least two treatment attempts
- Your cancer is considered relapsed/refractory, or you cannot get a stem cell transplant
- You must be able to donate cells for the study (leukapheresis) and the collected cells must be accepted for manufacturing
- You must be expected to live more than 12 weeks and be well enough to participate (performance status level must be at least 50)
- Your screening tests must show your organs are working well enough for treatment (details are checked by the study team)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This trial tests a new CAR T-cell treatment for people with certain blood cancers (like some leukemias and lymphomas) that have not responded to other treatments. It may help even if previous CD19-targeted therapies have stopped working.
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
Hear when a new Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.